Up­dat­ed: Form 483 for UCB's Swiss site notes de­fi­cien­cies in qual­i­ty con­trol op­er­a­tions

The FDA on Tues­day re­leased a pre­vi­ous­ly un­pub­lished Form 483 is­sued to UCB’s man­u­fac­tur­ing site in Fri­bourg, Switzer­land, with four ob­ser­va­tions in­clud­ing one that notes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER